McKesson Research and Development Expenses 2010-2023 | MCK

McKesson annual/quarterly research and development expenses history and growth rate from 2010 to 2023. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • McKesson research and development expenses for the quarter ending December 31, 2023 were $M, a NAN% increase year-over-year.
  • McKesson research and development expenses for the twelve months ending December 31, 2023 were $0M, a NAN% increase year-over-year.
  • McKesson annual research and development expenses for 2023 were $0B, a NAN% decline from 2022.
  • McKesson annual research and development expenses for 2022 were $0B, a NAN% decline from 2021.
  • McKesson annual research and development expenses for 2021 were $0B, a NAN% decline from 2020.
McKesson Annual Research and Development Expenses
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $125
2017 $341
2016 $392
2015 $392
2014 $457
2013 $433
2012 $402
2011 $407
2010 $376
2009 $364
McKesson Quarterly Research and Development Expenses
(Millions of US $)
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $71.697B $308.951B
McKesson Corporation is a health care services and information technology company. McKesson operates through two segments: The Distribution Solutions segment distributes branded and generic pharmaceutical drugs along with other healthcare-related products on a global basis worldwide. The segment also provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. In addition, the segment provides specialty pharmaceutical solutions for pharmaceutical manufacturers including offering multiple distribution channels and study access to oncology physicians. The Technology Solutions segment provides enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions. per segment realignment, McKesson reported revenues through four segments: U.S. Pharmaceutical and Specialty Solutions, Internation, Medical-Surgical Solutions and Prescription Technology Solutions.
Stock Name Country Market Cap PE Ratio
Becton Dickinson (BDX) United States $67.917B 19.22
West Pharmaceutical Services (WST) United States $25.821B 46.28
Cardinal Health (CAH) United States $23.731B 13.57
Align Technology (ALGN) United States $20.934B 40.42
Cooper (COO) United States $19.073B 28.86
Labcorp (LH) United States $17.804B 15.33
Henry Schein (HSIC) United States $9.318B 16.58
DENTSPLY SIRONA (XRAY) United States $5.839B 15.12
Merit Medical Systems (MMSI) United States $4.788B 26.24
Patterson (PDCO) United States $2.279B 10.92
CONMED (CNMD) United States $2.232B 20.24
STAAR Surgical (STAA) United States $2.145B 82.36
Atrion (ATRI) United States $0.837B 44.72
Lifevantage (LFVN) United States $0.089B 11.48
Pro-Dex (PDEX) United States $0.066B 33.33
Biolase (BIOL) United States $0.005B 0.00